Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)
Interim guidance
15 March 2022
| COVID-19: Vaccines
![Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™)](https://iris.who.int/bitstream/handle/10665/352466/WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222-2022.1-eng.pdf.jpg?sequence=12)
Overview
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence
summary included in the background document referenced below.
This document has been updated: Version 15 March 2022.
For translations of this document in other languages, click here.
Related document:
- Latest GRADE and ETR tables
- Background document on the AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca
Archived versions:
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). Version 30 July 2021
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). Version 21 April 2021
- Interim guidance for the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19. Version 10 February 2021
WHO Team
Immunization, Vaccines and Biologicals (IVB),
WHO Headquarters (HQ)
Number of pages
12
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/AZD1222/2021.3
Copyright
